Must-reads for professionals working in the field of Immunologic therapies and cancer

For professionals working in the fields of immunologic therapies and cancer. We curate thousands of sources from around the world and bring you our newsletter with the most important and relevant news twice a week.

Targovax’s Cancer Immunotherapy TG02 Is Safe, Initial Trial Review Shows

Immuno-oncologynews.com … Targovax’s immunotherapy for solid tumors has passed its first clinical trial safety review. The company is conducting a Phase 1b trial of TG02 alone, and in combination with Merck’s Keytruda, as a treatment for colorectal cancer stemming from a Ras protein mutation. TG02 is a cancer vaccine designed to trigger an immune response to a tumor…